Intellia Therapeutics Announces 2024 Annual Meeting of Stockholders on June 12

TL;DR

<b>Intellia Therapeutics will hold its 2024 Annual Meeting of Stockholders online on June 12, 2024.</b>

AI Summary

Intellia Therapeutics, Inc. (NTLA) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. The 2024 Annual Meeting of Stockholders for Intellia Therapeutics, Inc. will be held online on June 12, 2024, at 9:00 a.m. Eastern Time. Stockholders can attend the meeting virtually via the internet at www.virtualshareholdermeeting.com/NTLA2024. The filing is a Definitive Proxy Statement (DEF 14A) filed on April 29, 2024. The company's fiscal year ends on December 31. Intellia Therapeutics, Inc. is incorporated in Delaware and headquartered in Cambridge, MA.

Why It Matters

For investors and stakeholders tracking Intellia Therapeutics, Inc., this filing contains several important signals. This filing provides crucial information for stockholders regarding the upcoming annual meeting, including how to attend and vote, which is essential for corporate governance and shareholder participation. As a DEF 14A filing, it details executive compensation, board nominations, and other important corporate matters that directly impact shareholder value and company direction.

Risk Assessment

Risk Level: low — Intellia Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement and does not contain new financial or operational data that would indicate a change in risk.

Analyst Insight

Review the proxy statement to understand executive compensation, board proposals, and voting procedures before the June 12, 2024, Annual Meeting.

Key Numbers

• June 12, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
• 9:00 a.m. Eastern Time — Meeting Time (2024 Annual Meeting of Stockholders)
• 0000950170-24-049875 — Accession Number (SEC Filing)
• DEF 14A — Form Type (SEC Filing)
• 2024-04-29 — Filing Date (DEF 14A)

Key Players & Entities

• Intellia Therapeutics, Inc. (company) — Registrant name
• NTLA (company) — Ticker symbol
• 2024 Annual Meeting of Stockholders (event) — Meeting name
• June 12, 2024 (date) — Annual Meeting date
• Cambridge, Massachusetts (location) — Company headquarters
• April 29, 2024 (date) — Filing date

FAQ

Industry Context

Intellia Therapeutics operates in the biotechnology sector, focusing on developing CRISPR-based therapies.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs proxy solicitations.

What Investors Should Do

1. Review the proxy materials for proposals and director nominations.
2. Determine voting method and cast votes before the June 12, 2024 deadline.
3. Attend the virtual meeting to observe proceedings and ask questions.

Key Dates

• 2024-06-12: 2024 Annual Meeting of Stockholders — Key date for shareholder voting and participation.
• 2024-04-29: DEF 14A Filing — Date the proxy statement was filed with the SEC.

Year-Over-Year Comparison

This is a DEF 14A filing for the 2024 Annual Meeting, providing information on corporate governance and executive compensation.

Filing Documents

• ntla-20240429.htm (DEF 14A) — 1758KB
• img109974557_0.jpg (GRAPHIC) — 28KB
• img109974557_1.jpg (GRAPHIC) — 28KB
• img109974557_2.jpg (GRAPHIC) — 26KB
• img109974557_3.jpg (GRAPHIC) — 39KB
• img109974557_4.jpg (GRAPHIC) — 489KB
• img109974557_5.jpg (GRAPHIC) — 190KB
• 0000950170-24-049875.txt (&nbsp;) — 4226KB
• ntla-20240429.xsd (EX-101.SCH) — 26KB
• ntla-20240429_htm.xml (XML) — 140KB

From the Filing

DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 INTELLIA THERAPEUTICS, INC. (Name of registrant as specified in its charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 INTELLIA THERAPEUTICS, INC. 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 NOTICE OF 2024 ANNUAL MEETING OF STOCKHOLDERS To be held June 12, 2024 You are invited to attend the 2024 Annual Meeting of Stockholders (the "Annual Meeting") of Intellia Therapeutics, Inc. (the "Company"), which will be held online on Wednesday, June 12, 2024 at 9:00 a.m. Eastern Time. You may attend the meeting virtually via the Internet at www.virtualshareholdermeeting.com/NTLA2024, where you will be able to vote electronically and submit questions. You will need the 16-digit control number included with the Notice of Internet Availability of Proxy Materials being mailed to you separately in order to attend the Annual Meeting. Stockholders of record at the close of business on April 15, 2024, the record date for the Annual Meeting, are entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement of the Annual Meeting. The purpose of the Annual Meeting is the following: 1. Election of two class II directors to our board of directors, each to serve until the 2027 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal 2. Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 3. Approval, on a non-binding advisory basis, of the compensation of our named executive officers; 4. Approval of a second amendment to our Second Amended and Restated Certificate of Incorporation, as amended, to limit the liability of certain officers of the Company as permitted by recent amendments to the Delaware General Corporation Law; and 5. Transaction of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof. You can find more information on each of the matters to be voted on at the Annual Meeting, including information regarding the nominees for election to our board of directors, in the accompanying proxy statement. The board of directors recommends a vote: "FOR" the election of each of the two nominees for class II directors, "FOR" the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024, "FOR" the approval, on a non-binding advisory basis, of the compensation of our named executive officers, as disclosed in the accompanying proxy statement, and "FOR" the approval of a second amendment to our Second Amended and Restated Certificate of Incorporation, as amended, to limit the liability of certain officers of the Company as permitted by recent amendments to the Delaware General Corporation Law. The Company is following the U.S. Securities and Exchange Commission's "Notice and Access" rule that allows companies to furnish their proxy materials by posting them on the Internet. As a result, we are mailing to our stockholders a Notice of Internet Availability of Proxy Materials (the "Notice") instead of a paper copy of the accompanying proxy statement and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "2023 Annual Report"). We are mailing the Notice on or about April 29, 2024, and it contains instructions on how to access both the 2023 Annual Report and accompanying proxy statement (the "Proxy Materials") over the Internet. This method provides our stockholders with expedited access to Proxy Materials and not only lowers the cost of printing and distribution but also reduces the environmental impact of the Annual Meeting. If you would like to receive a paper copy of the Proxy Materials, free of charge, please follow the instructions on the Notice. Whether or not you expect to attend the Annual Meeting online, we encourage you to read the accompanying proxy statement and vote your shares as promptly as possible to ensure your representation and the presence of a quorum at the Annual Meeting on the Internet as descr

View Full Filing

View this DEF 14A filing on SEC EDGAR